APP and Alzheimer disease: Investigating the early stage of the disease, hBM-MSCs-EVs promoted the Aβ plaque disaggregation in 5-month-old APP/PS1dE9 AD mice and prevented new plaque formation in 3-month-old mice, likely via direct interaction with Aβ plaques and delivery of Aβ-degrading enzymes [33].